Tonix Pharm Holdings (TNXP)

Jun 5, 2025, 7:00 AM EDT - 16 hours ago

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

May 22, 2025, 7:00 AM EDT - 14 days ago

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

May 21, 2025, 7:00 AM EDT - 15 days ago

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

May 14, 2025, 7:00 AM EDT - 22 days ago

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

May 12, 2025, 4:30 PM EDT - 24 days ago

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Apr 29, 2025, 9:05 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Apr 24, 2025, 7:55 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Apr 16, 2025, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Apr 9, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Apr 7, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Apr 2, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Mar 31, 2025, 7:00 AM EDT - 2 months ago

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Mar 27, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Mar 26, 2025, 2:30 AM EDT - 2 months ago

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

Mar 25, 2025, 8:16 AM EDT - 2 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

ARQT

Mar 24, 2025, 8:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Mar 20, 2025, 7:00 AM EDT - 2 months ago

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Mar 19, 2025, 8:15 AM EDT - 2 months ago

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ABSI HQY

Mar 18, 2025, 4:30 PM EDT - 2 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 13, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

Mar 12, 2025, 7:30 AM EDT - 3 months ago

Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

Mar 11, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

Mar 10, 2025, 8:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate

Mar 5, 2025, 7:00 AM EST - 3 months ago

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

Mar 4, 2025, 7:00 AM EST - 3 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

Feb 7, 2025, 8:30 AM EST - 4 months ago

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Feb 6, 2025, 8:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Feb 5, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

Feb 4, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer

Feb 3, 2025, 8:05 AM EST - 4 months ago

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split

Dec 23, 2024, 8:00 AM EST - 5 months ago

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

Dec 17, 2024, 10:59 AM EST - 6 months ago

FDA accepts Tonix's NDA for non-opioid fibromyalgia drug TNX-102 SL

Dec 17, 2024, 8:00 AM EST - 6 months ago

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

Dec 16, 2024, 11:40 AM EST - 6 months ago

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights

Dec 9, 2024, 7:30 AM EST - 6 months ago

Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers

Nov 26, 2024, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference

Nov 21, 2024, 4:27 AM EST - 7 months ago

Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and Apnimed

Nov 18, 2024, 4:05 PM EST - 7 months ago

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual

Nov 14, 2024, 7:30 AM EST - 7 months ago

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Nov 13, 2024, 4:05 PM EST - 7 months ago

Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Nov 13, 2024, 9:05 AM EST - 7 months ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals

Nov 1, 2024, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

Oct 29, 2024, 8:00 AM EDT - 7 months ago

Tonix Pharmaceuticals to Present at BIO-Europe® 2024

Oct 25, 2024, 8:00 AM EDT - 7 months ago

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Oct 16, 2024, 8:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)

Oct 8, 2024, 8:30 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals

Oct 1, 2024, 7:30 AM EDT - 8 months ago

The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions

Sep 27, 2024, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines

Sep 19, 2024, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines